Related Experiment Video
Updated: Jun 5, 2026
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
The optimal pharmacological formula for percutaneous coronary intervention
Davide Capodanno1, Corrado Tamburino, George Dangas
1University of Catania, Ferrarotto Hospital, Via Citelli, 6, 95124 Catania, Italy.
Expert Opinion on Pharmacotherapy
|January 21, 2011
Summary
Optimizing adjunctive pharmacotherapy after percutaneous coronary intervention (PCI) is crucial. Recent guideline updates reflect new evidence on antiplatelet drugs and anticoagulants to improve patient outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Adjunctive pharmacotherapy significantly impacts percutaneous coronary intervention (PCI) outcomes.
- Aggressive management of coronary risk factors and lifestyle changes further reduce morbidity and mortality.
- Recent clinical trials led to updated PCI guidelines on antiplatelet and anticoagulant use.
Purpose of the Study:
- To provide an updated overview of adjunctive pharmacological therapy in revascularization.
- To focus on recent trial results and future research directions in interventional pharmacology.
Main Methods:
- Review of current evidence on adjunctive pharmacological therapy for PCI.
- Analysis of recent randomized clinical trials and guideline updates.
Main Results:
- Updated recommendations for antiplatelet agents and parenteral anticoagulants in PCI.
- Emphasis on risk factor management and lifestyle changes alongside pharmacotherapy.
Conclusions:
- Individualizing pharmacotherapy based on patient needs and risk is key for balancing safety and efficacy.
- Future research will likely focus on novel antiplatelet agents and selective coagulation factor inhibitors.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...